Scarica l'app Stockscreener
6.53
2.10%
-0.14
Dopo l'orario di chiusura:
6.51
-0.02
-0.31%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché FOLD Giù?
Forum
Previsione
Precedente Chiudi:
$6.67
Aprire:
$6.64
Volume 24 ore:
4.24M
Relative Volume:
1.34
Capitalizzazione di mercato:
$2.28B
Reddito:
$493.67M
Utile/perdita netta:
$-104.69M
Rapporto P/E:
-19.21
EPS:
-0.34
Flusso di cassa netto:
$-31.51M
1 W Prestazione:
-11.64%
1M Prestazione:
-12.93%
6M Prestazione:
-44.38%
1 anno Prestazione:
-37.21%
Intervallo 1D:
$6.50
$6.73
Intervallo di 1 settimana:
$6.50
$7.705
Portata 52W:
$6.20
$12.65
Amicus Therapeutics Inc Stock (FOLD) Company Profile
Nome
Amicus Therapeutics Inc
Settore
Industria
Telefono
(609) 662-2000
Indirizzo
47 HULFISH STREET, PRINCETON, NJ
Confronta FOLD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FOLD
Amicus Therapeutics Inc
|
6.53 | 2.28B | 493.67M | -104.69M | -31.51M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-13 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-09-06 | Iniziato | Jefferies | Buy |
| 2024-05-30 | Iniziato | Wells Fargo | Overweight |
| 2024-05-14 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-12-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-04-13 | Ripresa | Goldman | Neutral |
| 2022-01-14 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-15 | Aggiornamento | Stifel | Hold → Buy |
| 2021-09-30 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-07-19 | Ripresa | BTIG Research | Buy |
| 2021-05-27 | Iniziato | Needham | Hold |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-04-14 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2021-03-02 | Iniziato | Stifel | Hold |
| 2021-02-12 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-12 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-12-28 | Ripresa | Cantor Fitzgerald | Overweight |
| 2020-12-10 | Downgrade | Citigroup | Buy → Neutral |
| 2020-11-11 | Iniziato | Berenberg | Hold |
| 2020-06-17 | Iniziato | BTIG Research | Buy |
| 2020-02-04 | Ripresa | Cantor Fitzgerald | Overweight |
| 2019-11-12 | Reiterato | H.C. Wainwright | Buy |
| 2019-06-17 | Iniziato | H.C. Wainwright | Buy |
| 2019-06-05 | Reiterato | Cantor Fitzgerald | Overweight |
| 2019-04-05 | Iniziato | Janney | Buy |
| 2019-01-30 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-10-29 | Iniziato | Citigroup | Neutral |
| 2018-08-17 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2017-10-06 | Ripresa | Goldman | Neutral |
| 2017-09-13 | Reiterato | Chardan Capital Markets | Buy |
| 2017-08-10 | Reiterato | Chardan Capital Markets | Buy |
| 2017-01-24 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2016-05-18 | Iniziato | BofA/Merrill | Buy |
| 2016-04-14 | Iniziato | Robert W. Baird | Neutral |
| 2016-04-12 | Reiterato | Chardan Capital Markets | Buy |
| 2015-09-16 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2015-06-16 | Reiterato | Chardan Capital Markets | Buy |
Mostra tutto
Amicus Therapeutics Inc Borsa (FOLD) Ultime notizie
Pompe Disease Market Expected to Experience Major Growth - openPR.com
Voya Investment Management LLC Sells 743,492 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Purchased by Aquatic Capital Management LLC - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Acquired by PDT Partners LLC - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Acquired by Tower Research Capital LLC TRC - MarketBeat
Amicus Therapeutics First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Marshall Wace LLP Boosts Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Dark Forest Capital Management LP Purchases Shares of 38,148 Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
UBS Raises Price Target for Amicus Therapeutics (FOLD) to $22, M - GuruFocus
Amicus Therapeutics (FOLD) Target Price Lowered by Goldman Sachs | FOLD Stock News - GuruFocus
FOLD Q1 Earnings and Sales Miss Estimates, Stock Falls - TradingView
UBS Boosts Amicus (FOLD) Price Target Despite Revised Pompe Dise - GuruFocus
UBS Boosts Amicus (FOLD) Price Target Despite Revised Pompe Disease Outlook | FOLD Stock News - GuruFocus
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q1 2025 Earnings Call Transcript - Insider Monkey
UBS Adjusts Amicus Therapeutics Price Target to $22 From $21, Maintains Buy Rating - marketscreener.com
Press Release Distribution & PR Platform - ACCESS Newswire
Dimerix and Amicus to commercialise DMX-200 in US - MSN
Amicus Therapeutics Inc Reports Q1 2025 Earnings: EPS of -$0.07 - GuruFocus
Dimerix strikes $601M Amicus deal for kidney disease drug DMX-200 - BioWorld MedTech
Dimerix and Amicus Therapeutics Announce Exclusive License Agree - GuruFocus
Amicus Therapeutics Turns to Non-GAAP Q1 Earnings, Revenue Rises; Shares Down - marketscreener.com
Earnings call transcript: Amicus Therapeutics reports Q1 2025 loss, stock drops - Investing.com India
Amicus Therapeutics (FOLD) Q1 Earnings and Revenues Lag Estimates - Yahoo Finance
Amicus Therapeutics: Q1 Earnings Snapshot - San Antonio Express-News
Amicus Therapeutics Announces First Quarter 2025 Financial Results and Corporate Updates - The Manila Times
Amicus Therapeutics Q1 2025 slides: 15% revenue growth, new kidney disease program - Investing.com
Amicus (FOLD) Shows Strong Revenue Growth Amid Recent Quarter Ch - GuruFocus
BRIEF-Amicus Therapeutics Q1 Revenue USD 125.2 Million Vs. IBES Estimate USD 135.9 Million - TradingView
Brokerages Set Amicus Therapeutics, Inc. (NASDAQ:FOLD) Target Price at $16.75 - MarketBeat
Amicus Therapeutics Signs Exclusive License Deal for Dimerix Kidney Disease Therapy - marketscreener.com
Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States - GlobeNewswire
Amicus Therapeutics Q1 2025 Earnings Preview - MSN
Amicus Therapeutics Earnings Preview - Nasdaq
Fabry Disease Market: Epidemiology, Drugs, Companies, DelveInsight | Amicus Therapeutics, CHIESI Farmaceutici and Protalix Biotherapeutics, Sanofi (Genzyme), Takeda Pharmaceuticals, Sangamo Therapeuti - The Globe and Mail
LATAM Fabry Disease Market Set to Witness Significant Growth - openPR.com
Amicus Therapeutics (FOLD) to Release Earnings on Thursday - MarketBeat
Russell Investments Group Ltd. Grows Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Rock Springs Capital Management LP Purchases 1,349,145 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Jump Financial LLC Lowers Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics to Report Q1 Earnings: What's in the Cards? - MSN
Amicus Therapeutics (FOLD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
Is Amicus Therapeutics, Inc. (FOLD) Among the Best Guru Stocks to Buy According to Wall Street Analysts? - Insider Monkey
Amicus Therapeutics Inc Azioni (FOLD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.39%
3.66%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):